Drug intelligence / Profile preview

RZ-iDA001

Development stage: Preclinical
Lead developer: Guangzhou Regenverse Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Implant

Overview

RZ-iDA001 is an allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic progenitor cell therapy under development by Guangzhou Regenverse Therapeutics. It is designed to treat both idiopathic and genetic forms of Parkinson's disease by restoring dopaminergic neurons and their associated functions within the nigrostriatal pathway and striatal dopaminergic circuitry (specifically D1 and D2 receptor circuits). The therapy aims to address the underlying neuronal loss characteristic of Parkinson's disease. As of late 2024, the program is in the preclinical stage, undergoing GLP pre-clinical validation.

Other names: RZ-iDA001RZ-iDA-001RZ-iDA 001

Beyond the preview

Go deeper on RZ-iDA001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RZ-iDA001.

Explore the full profile